- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04633759
Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis (BFR-MS)
Feasibility of Low-load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis and Marked Mobility Restriction
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Primary Aim of this research study is to determine the feasibility of 8 weeks of physical therapy strengthening exercises using blood flow restriction (BFR) in people with multiple sclerosis (MS) who have moderate-to-severe walking problems. BFR training involves placing a cuff on the leg being exercised in order to restrict blood flow. The cuff is attached to a specialized device that automatically detects the appropriate amount of pressure to place on the limb. Testing will occur before and after the 8-week treatment period.
Specific Aim 1: Determine the feasibility of BFR by assessing recruitment rate, retention, adherence, satisfaction, and safety.
Hypothesis: Feasibility will be demonstrated by: 1) enrolling 20 participants in 8 months, 2) retaining at least 16 (80%) participants, 3) 80% adherence to intervention, 4) 90% satisfaction with intervention, and 5) no serious adverse events related to the intervention.
Specific Aim 2: Determine changes in knee and hip extension, hip abduction, and ankle plantarflexion muscle strength after the 8-week intervention.
Hypothesis: Following intervention there will be clinically important within-group strength changes that correspond to established minimal detectable change values and which can be characterized as having at least a moderate effect size as defined by Cohen's d.
Exploratory Aim: Explore changes in functional mobility (30-Second Sit-to-Stand, Berg Balance Scale, Timed 25-Foot Walk. 10-day average activity level) and self-report measures (12-Item MS Walking Scale, Modified Fatigue Impact Scale, MS Impact Scale-29, and Patient-Specific Functional Scale) after the 8-week intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adults ages 18-70
- Neurologist-confirmed diagnosis of multiple sclerosis
Expanded Disability Status Scale (EDSS) 6.0 to 7.0
- EDSS 6.0: unilateral assistance (cane or crutch) required to walk at least 100 meters with or without resting
- EDSS 6.5: Bilateral assistance (cane or crutch) required to walk at least 20 meters with or without resting
- EDSS 7.0: unable to walk 5 meters even with aid, essentially restricted to wheelchair; wheels self and transfers alone; up and about in wheelchair some 12 hours a day
Exclusion Criteria:
- EDSS 7.5 or greater: Restricted to wheelchair for all mobility, unable to walk more than a few steps, even with walking aid
- EDSS 5.5 or less: Able to walk more than 100 meters without walking aid or rest
- Unable to provide consent or follow simple directions
- Prior history of Deep Venous Thrombosis/ Pulmonary Embolism
- History of peripheral vascular disease, thrombophilia or other clotting disorders
- Patient report of easy bruising
- Any comorbid conditions or pain that substantially affects physical function or would interfere with the participant's ability to safely complete rehabilitation (e.g. neurologic, vascular, cardiac problems, orthopedic, or ongoing medical treatments) as determined by a neurologist of physical therapist
- Severe lower extremity spasticity as defined as Modified Ashworth scale > 2
- Currently undergoing supervised resistance training with a physical therapist or other exercise professional
- Use of Blood Flow Restriction currently or in the previous 3 months prior to enrollment
- MS-related exacerbation or changes to their disease-modifying drug therapy in the month prior to enrollment
- Inability to tolerate pressure cuff during baseline assessment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Blood Flow Restriction Exercise
Participant will participate in a supervised low load blood flow restriction exercise program twice a week for 8 weeks.
|
Following a 5-minute low intensity warm-up, the BFR cuff will be placed at the most proximal portion of the leg and dosed following standard BFR guidelines: 1 set of 30 reps, then 3 sets of 15 reps at 20-30% 1RM with up to 80% limb occlusion.
Exercises will target bilateral 1) knee and hip extension, 2) hip abduction, and 3) ankle plantarflexion, as these muscles are important for functional mobility in people with MS.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in knee extension muscle strength
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Knee extension muscle strength measured by hand-held dynamometry
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in hip abduction muscle strength
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Hip abduction muscle strength measured by hand-held dynamometry
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in ankle plantarflexion muscle strength
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Ankle plantarflexion muscle strength measured by hand-held dynamometry
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in 30-second sit-to-stand completions
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Functional mobility test measuring the number of sit to stand cycles a participant can complete in 30 seconds
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in Berg Balance Scale
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Functional mobility test measuring the participant's ability to balance in different postures.
Scores range from 0 to 56 points, with 0-20 points indicating wheelchair bound, 21-40 indicating walking with assistance, and 41-56 indicating walking independently.
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in timed 25-foot walk
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Functional mobility test measuring the time it takes a participant to walk 25 feet
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in activity level
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
10-day average of activity level as measured by a wearable activity monitor
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in 12-Item MS Walking Scale
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Self-report questionnaire measuring walking ability with scores ranging from 12 points (no difficulty walking, to 60 points (extremely limited or no walking)
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in Modified Fatigue Impact Scale
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Self-report questionnaire measuring fatigue caused by MS with scores ranging from 0 (no impact of fatigue in the past 4 weeks) to 84 (maximum impact of fatigue in the past 4 weeks)
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in MS Impact Scale-29
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Self-report questionnaire measuring the impact of MS on daily activity with scores ranging from 29 (MS has no impact on my daily life) to 145 (MS extremely impacts my daily life)
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Change in MS Patient-Specific Function Scale
Time Frame: Measured at Baseline (Week 0) and Post Test (Week 9)
|
Self-report questionnaire measuring the ability of the participant to do three self-identified activities.
Scores of each of the 3 activities range from 0 (unable to perform) to 10 (able to perform without difficulty)
|
Measured at Baseline (Week 0) and Post Test (Week 9)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20-0695
- 205593 (Other Grant/Funding Number: Consortium of Multiple Sclerosis Centers)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Queen Mary University of LondonTakeda Pharmaceuticals International, Inc.RecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited Kingdom
Clinical Trials on Blood Flow Restriction Exercise
-
George Fox UniversityUnknownMuscle Weakness | Can Blood Flow Restriction Therapy Augments Strength Gains in the Rotator CuffUnited States
-
Universitat Internacional de CatalunyaUnknownBone Diseases | Exercise | Osteoporosis | Osteoporosis, Postmenopausal
-
University of West AtticaEnrolling by invitationLateral EpicondylitisGreece
-
Womack Army Medical CenterThe Geneva Foundation; Telemedicine & Advanced Technology Research CenterTerminatedAchilles TendinopathyUnited States
-
University of IowaCompletedKnee Osteoarthritis | Symptomatic Knee OsteoarthritisUnited States
-
George Fox UniversityUnknownMuscular WeaknessUnited States
-
Eastern Mediterranean UniversityCompletedPhysical PerformanceCyprus
-
Paulista UniversityRecruiting
-
Dokuz Eylul UniversityCompletedHealthy IndividualsTurkey
-
Marquette UniversityUniversity of Illinois at Chicago; Medical College of WisconsinNot yet recruiting